WO2025248450 - S-RELEASING MESALAMINE ANALOGS
National phase entry is expected:
Publication Number
WO/2025/248450
Publication Date
04.12.2025
International Application No.
PCT/IB2025/055474
International Filing Date
27.05.2025
Title **
[English]
S-RELEASING MESALAMINE ANALOGS
[French]
ANALOGUES DE MÉSALAMINE LIBÉRANT DU H2S
Applicants **
ANTIBE THERAPEUTICS, INC.
Inventors
DOVE, Peter Martin
JARDOSH, Hardik Hemantkumar
VIRK, Tarunpreet Singh
PATEL, Jigneshkumar Jashbhai
MAHMOUD, Ahmed Salaheldin Megahed
TO, Quang Huy
OMEARA, Jeff
BELL, Mark
VAUGHAN, David J.
Priority Data
63/652,221
28.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4201 | |
| EPO | Filing, Examination, Granting | 61582 | |
| Japan | Filing, Examination, Granting | 4004 | |
| South Korea | Filing, Examination, Granting | 6006 | |
| USA | Filing, Examination, Granting | 16140 |

Total:
91,933
Contact Us
Abstract[English]
S-releasing mesalamine analogs of Formula I, and pharmaceutically acceptable salts, solvates and/or prodrugs thereof. The application also includes pharmaceutical compositions comprising these compounds and methods of treating diseases, disorders or conditions that benefit from treatment with mesalamine using these compounds (I).[French]
S de formule I, et des sels, solvates et/ou promédicaments pharmaceutiquement acceptables de ceux-ci. L'invention concerne également des compositions pharmaceutiques comprenant ces composés et des méthodes de traitement de maladies, de troubles ou d'états pour lesquels un traitement avec de la mésalamine à l'aide de ces composés (I) est bénéfique.